A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants
NCT07525947
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of JADE101 in healthy Japanese and Chinese participants.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Healthy Volunteers (HV)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Jade Biosciences, Inc.
- Last updated on ClinicalTrials.gov
- June 4, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Parexel Early Phase Clinical Unit (EPCU) · Glendale, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.